|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chan JK, Cheung MK, Husain A, Teng NN,
West D, Whittemore AS, Berek JS and Osann K: Patterns and progress
in ovarian cancer over 14 years. Obstet Gynecol. 108:521–528. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prat J: New insights into ovarian cancer
pathology. Ann Oncol. 23(Suppl 10): x111–x117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herzog TJ and Pothuri B: Ovarian cancer: A
focus on management of recurrent disease. Nat Clin Pract Oncol.
3:604–611. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoskins P, Eisenhauer E, Vergote I,
Dubuc-Lissoir J, Fisher B, Grimshaw R, Oza A, Plante M, Stuart G
and Vermorken J: Phase II feasibility study of sequential couplets
of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary
treatment for advanced epithelial ovarian cancer: A national cancer
institute of canada clinical trials group study. J Clin Oncol.
18:4038–4044. 2000.PubMed/NCBI
|
|
10
|
Theriault C, Pinard M, Comamala M,
Migneault M, Beaudin J, Matte I, Boivin M, Piché A and Rancourt C:
MUC16 (CA125) regulates epithelial ovarian cancer cell growth,
tumorigenesis and metastasis. Gynecol Oncol. 121:434–443. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dorigo O and Berek JS: Personalizing CA125
levels for ovarian cancer screening. Cancer Prev Res (Phila).
4:1356–1359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakajo M, Nakajo M, Nakayama H, Jinguji M,
Nakabeppu Y, Higashi M, Nakamura Y, Sato M and Yoshiura T:
Dexamethasone suppression FDG PET/CT for differentiating between
true- and false-positive pulmonary and mediastinal lymph node
metastases in non-small cell lung cancer: A pilot study of FDG
PET/CT after oral administration of dexamethasone. Radiology.
279:246–253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fujimoto A, Furuta M, Totoki Y, Tsunoda T,
Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, et
al: Whole-genome mutational landscape and characterization of
noncoding and structural mutations in liver cancer. Nat Genet.
48:500–509. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen D, Sun Q, Cheng X, Zhang L, Song W,
Zhou D, Lin J and Wang W: Genome-wide analysis of long noncoding
RNA (lncRNA) expression in colorectal cancer tissues from patients
with liver metastasis. Cancer Med. May 11–2016.(Epub ahead of
print). View
Article : Google Scholar
|
|
15
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prensner JR and Chinnaiyan AM: The
emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao B, Song N, Zhang M, Di C, Yang Y, Lu
Y, Chen R, Lu ZJ and Guo M: Systematic study of novel lncRNAs in
different gastrointestinal cancer cells. Discov Med. 21:159–171.
2016.PubMed/NCBI
|
|
18
|
Wang L, Li J, Zhao H, Hu J, Ping Y, Li F,
Lan Y, Xu C, Xiao Y and Li X: Identifying the crosstalk of
dysfunctional pathways mediated by lncRNAs in breast cancer
subtypes. Mol Biosyst. 12:711–720. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng HT, Shi DB, Wang YW, Li XX, Xu Y,
Tripathi P, Gu WL, Cai GX and Cai SJ: High expression of lncRNA
MALAT1 suggests a biomarker of poor prognosis in colorectal cancer.
Int J Clin Exp Pathol. 7:3174–3181. 2014.PubMed/NCBI
|
|
20
|
Pang EJ, Yang R, Fu XB and Liu YF:
Overexpression of long non-coding RNA MALAT1 is correlated with
clinical progression and unfavorable prognosis in pancreatic
cancer. Tumour Biol. 36:2403–2407. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang HM, Yang FQ, Chen SJ, Che J and
Zheng JH: Upregulation of long non-coding RNA MALAT1 correlates
with tumor progression and poor prognosis in clear cell renal cell
carcinoma. Tumour Biol. 36:2947–2955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen L, Chen L, Wang Y, Jiang X, Xia H and
Zhuang Z: Long noncoding RNA MALAT1 promotes brain metastasis by
inducing epithelial-mesenchymal transition in lung cancer. J
Neurooncol. 121:101–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han
Z, Sui H, Tang Y, Wang Y, Liu N, et al: Long non-coding RNA MALAT1
promotes tumour growth and metastasis in colorectal cancer through
binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2
complex. Br J Cancer. 111:736–748. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong Y, Liang G, Yuan B, Yang C, Gao R and
Zhou X: MALAT1 promotes the proliferation and metastasis of
osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol.
36:1477–1486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F
and Liu Y: TGF-β-induced upregulation of malat1 promotes bladder
cancer metastasis by associating with suz12. Clin Cancer Res.
20:1531–1541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding
Q, Weng H, Shu YJ, Liu TY, Jiang L, et al: MALAT1 promotes the
proliferation and metastasis of gallbladder cancer cells by
activating the ERK/MAPK pathway. Cancer Biol Ther. 15:806–814.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
National Comprehensive Cancer Network.
NCCN Clinical Practice Guidelines in Oncology: (NCCN
Guidelines®) Ovarian Cancer Including Fallopian Tube
Cancer and Primary Peritoneal Cancer. Version 1. 2015.http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdfAccessed.
May 5–2016
|
|
30
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: Ovary and primary peritoneal carcinoma.
AJCC Cancer Staging Manual (7th). Springer-Verlag. (NY). 419–428.
2010.
|
|
31
|
Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang
Q, Chen L, Pang X, Leng W and Bi F: Plasma miR-122 and miR-192 as
potential novel biomarkers for the early detection of distant
metastasis of gastric cancer. Oncol Rep. 31:1863–1870.
2014.PubMed/NCBI
|
|
32
|
Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J,
Wei M, Xu C, Wu C, Zhang Z, et al: Long non-coding RNA metastasis
associated in lung adenocarcinoma transcript 1 derived miniRNA as a
novel plasma-based biomarker for diagnosing prostate cancer. Eur J
Cancer. 49:2949–2959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Barakat RR, Markman M and Randall M:
Principles and Practice of Gynecologic Oncology (5th). Lippincott
Williams & Wilkins. 2009.
|
|
35
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang JF, Guo YJ, Zhao CX, Yuan SX, Wang
Y, Tang GN, Zhou WP and Sun SH: Hepatitis B virus X protein
(HBx)-related long noncoding RNA (lncRNA) down-regulated expression
by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by
targeting the intermediate filament protein vimentin. Hepatology.
57:1882–1892. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li H, Yu B, Li J, Su L, Yan M, Zhu Z and
Liu B: Overexpression of lncRNA H19 enhances carcinogenesis and
metastasis of gastric cancer. Oncotarget. 5:2318–2329. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Y, Liu X, Zhang H, Sun L, Zhou Y, Jin
H, Zhang H, Zhang H, Liu J, Guo H, et al: Hypoxia-inducible
lncRNA-AK058003 promotes gastric cancer metastasis by targeting
γ-synuclein. Neoplasia. 16:1094–1106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng
R, Wang Y, Huang J, Xu M, Yan J and Yu J: lncRNA H19/miR-675 axis
represses prostate cancer metastasis by targeting TGFBI. FEBS J.
281:3766–3775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Arita T, Ichikawa D, Konishi H, Komatsu S,
Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T,
et al: Circulating long non-coding RNAs in plasma of patients with
gastric cancer. Anticancer Res. 33:3185–3193. 2013.PubMed/NCBI
|
|
41
|
Tsui NB, Ng EK and Lo YM: Stability of
endogenous and added RNA in blood specimens, serum and plasma. Clin
Chem. 48:1647–1653. 2002.PubMed/NCBI
|
|
42
|
Ng EK, Tsui NB, Lau TK, Leung TN, Chiu RW,
Panesar NS, Lit LC, Chan KW and Lo YM: mRNA of placental origin is
readily detectable in maternal plasma. Proc Natl Acad Sci USA.
100:4748–4753. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Weber DG, Johnen G, Casjens S, Bryk O,
Pesch B, Jöckel KH, Kollmeier J and Brüning T: Evaluation of long
noncoding RNA MALAT1 as a candidate blood-based biomarker for the
diagnosis of non-small cell lung cancer. BMC Res Notes. 6:5182013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shen L, Chen L, Wang Y, Jiang X, Xia H and
Zhuang Z: Long noncoding RNA MALAT1 promotes brain metastasis by
inducing epithelial-mesenchymal transition in lung cancer. J
Neurooncol. 121:101–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
